MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology - BTG plc announced a collaboration with the Society of Interventional Oncology (SIO) to explore the role of interventional oncology alongside immuno-oncology - IO-Central.org / BTGplc.com
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology

 

NewswireToday - /newswire/ - London, United Kingdom, 2017/02/15 - BTG plc announced a collaboration with the Society of Interventional Oncology (SIO) to explore the role of interventional oncology alongside immuno-oncology - IO-Central.org / BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology.

Recent advances in cancer immunotherapy have led to an explosion of interest in immuno-oncology. Newly approved treatments, such as checkpoint inhibitors, have been shown to prolong overall survival but only for a limited proportion of cancer patients, and only in certain tumour types. Combining immuno-oncology agents with the minimally invasive, loco-regional therapies of interventional oncology has the potential to expand the number of cancer patients who could benefit. Further research is needed to understand the potential of these combinations.

SIO and BTG have established a working group to determine how best to explore the role of interventional oncology alongside immuno-oncology in the fight against cancer. This group, which includes interventional radiologists and immuno-oncologists, will identify unmet clinical needs and the critical areas of science that require further dedicated research. The working group plans to publish a white paper to guide research and clinical practice later this year.

This collaboration also establishes an independent research fund that will enable SIO to offer grant funding to independent investigators to address the critical unanswered questions for this combination therapy. SIO plans to fund collaborative research ranging from exploratory pilot projects to prospective clinical trials.

“SIO was founded to provide an optimal and necessary vehicle to nurture and support interventional oncology as the fourth pillar of cancer therapy worldwide. This research collaboration with BTG will help provide the resources necessary to further uncover how interventional oncology procedures may work synergistically when combined with another of the most cutting edge oncologic strategies immunotherapy,” stated S. Nahum Goldberg, MD, SIO Interventional/Immuno-oncology Working Group Chair, and Vice-Chair for Research and Head of the Interventional Oncology Unit, Hadassah Hebrew University Medical Center in Jerusalem, Israel.

Melanie Lee, Chief Scientific Officer of BTG, commented “As a leader in interventional oncology therapies, we believe this is an excellent opportunity to work with the scientific community and invest in generating new knowledge. Our portfolio includes embolic beads, radioactive microspheres, and cryotherapy solutions and this research will answer important questions about whether these minimally invasive therapies can expand the benefits of immuno-oncology drugs.”

How loco-regional therapies might help
Checkpoint inhibitors turn off signals that can inhibit the ability of T cells to kill cancer cells, but different tumours present different immunological challenges with responses also dependent on factors in the local tumour microenvironment. Loco-regional therapies, such as cryotherapy, embolisation or selective internal radiation therapy, de-bulk the tumour, which may make it easier for the immune system to tackle what remains. There is also some evidence that loco-regional therapies can also induce a tumour-specific immune response, releasing tumour antigens, and can help create an anti-tumour microenvironment. If combined with a checkpoint inhibitor or other immunotherapy, these effects could help make these agents more effective in a larger patient population. As loco-regional therapies are generally well tolerated, using them in combination is less likely to complicate the side-effect profile an important consideration given the immune-mediated side effects commonly experienced with checkpoint inhibitors.

About Society of Interventional Oncology (SIO)
SIO (io-central.org) serves as the only membership-based organization dedicated wholly to the emerging field of Interventional Oncology (IO), working to establish, nurture, and support IO as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. IO therapies, such as embolization and tumor ablation, combine the expertise of oncology and radiology and use imaging technology to diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. The society hosts the annual World Conference for Interventional Oncology (WCIO).

About BTG
BTG (btgplc.com) is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges.

Contacts
SIO: Amanda Winger O’Kane - Marketing & Communications
P: +1 202-367-1164 - E: aokane[.]io-central.org.

BTG: Andy Burrows - VP Corporate & Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

Stuart Hunt - Investor Relations Manager
P: +44(0)20 7575 1582 / M: +44(0)78 1577 8536

Ben Atwell/Simon Conway - FTI Consulting
P: +44(0)20 3727 1000.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®
DSM and Industry Partners Launch Coalition to Close the Loop on Dyneema® - The World’s Strongest Fiber™
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with its Differentiated Molecular Laboratory Information Management System
DSM Launches Three Times Faster-acting Form of Vitamin D Supplement in Australia to Support Immune Health
Ipsen Announces New Data from the Phase II CLARINET FORTE Study
South Carolina-based IMCS Awarded Major NIH Research Grant
Preventive Healthcare Measures to Combat Obesity and Lifestyle Diseases Steer Demand for Nutritional Lipids Globally Finds Frost & Sullivan
Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Venus Promotions

Visit  BizJobs.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)